14 July 1997 00:00 [Source: ICB]
BASF-Lynx Biosciences, the joint venture between BASF and the US biotechnology firm Lynx Therapeutics of Hayward, California, has received approval by German authorities to work with recombinant organisms at its Heidelberg laboratories.
Approval was granted under the German genetic engineering framework act and placed in safety category 1, which assumes no risk to either human life or the environment.
The company plans to carry out massive parallel signature sequencing (MPSS) to find a treatment for epilepsy.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.
Sample issue >>
My Account/Renew >>
Register for online access >>
|ICIS Top 100 Chemical Companies|
|Download the listing here >>|
Asian Chemical Connections